Ibrutinib, acalabrutinib, and zanubrutinib are Bruton tyrosine kinase inhibitors (BTKis) approved for treatment of chronic lymphocytic leukemia (CLL). In this study, researchers used data from package inserts, clinical trials, and real-world...
Ibrutinib, acalabrutinib, and zanubrutinib are Bruton tyrosine kinase inhibitors (BTKis) approved for treatment of chronic lymphocytic leukemia (CLL). In this study, researchers used data from package inserts, clinical trials, and real-world...
Systemic therapies for metastatic colorectal cancer (mCRC) have distinct safety and tolerability profiles. Adverse events (AEs) may occur and compromise the course of treatment, increase health care utilization and costs, and worsen patients’...
Systemic therapies for metastatic colorectal cancer (mCRC) have distinct safety and tolerability profiles. Adverse events (AEs) may occur and compromise the course of treatment, increase health care utilization and costs, and worsen patients’...
Drug waste poses a significant challenge in the field of health care, resulting in increased costs and environmental concerns. Using administrative claims data for Medicare patients from 15 practices in The US Oncology Network, researchers...
Drug waste poses a significant challenge in the field of health care, resulting in increased costs and environmental concerns. Using administrative claims data for Medicare patients from 15 practices in The US Oncology Network, researchers...
Conducting a thorough and systemic evaluation of practice readiness for value-based care (VBC) programs empowers practices to make informed decisions about VBC model participation. VBC programs like the Enhancing Oncology Model (EOM) offers...
Conducting a thorough and systemic evaluation of practice readiness for value-based care (VBC) programs empowers practices to make informed decisions about VBC model participation. VBC programs like the Enhancing Oncology Model (EOM) offers...
To fully understand and rectify impediments to optimal patient outcomes and experiences for patients with cancer, researchers reviewed health-related social needs (HRSN) to fully understand how to provide support to affected patients....
To fully understand and rectify impediments to optimal patient outcomes and experiences for patients with cancer, researchers reviewed health-related social needs (HRSN) to fully understand how to provide support to affected patients....
Manual electronic health records (EHR) can help bridge the gap between patients with cancer and survivorship resources. In this study, researchers conducted a pilot using a web-based clinical pathways decision-support platform to provide...
Manual electronic health records (EHR) can help bridge the gap between patients with cancer and survivorship resources. In this study, researchers conducted a pilot using a web-based clinical pathways decision-support platform to provide...
Delays in cancer treatment authorization often impede optimal patient care. In this retrospective assessment of payment rates, the Dana-Farber Cancer Institute explores payer approval decisions for on-pathway treatments.
Delays in cancer treatment authorization often impede optimal patient care. In this retrospective assessment of payment rates, the Dana-Farber Cancer Institute explores payer approval decisions for on-pathway treatments.
According to research published in the Journal of Clinical Oncology, clinical decision support (CDS) tools can foster an accelerated uptake of new therapies compared to non-users. In this study, researchers used a CDS tool called Flatiron...
According to research published in the Journal of Clinical Oncology, clinical decision support (CDS) tools can foster an accelerated uptake of new therapies compared to non-users. In this study, researchers used a CDS tool called Flatiron...
When previously identifying causes of delay in cancer treatment, existing workflows often did not provide consistent timelines estimated for providers to diagnose and treat patients. To reduce time to treatment, researchers employed a pilot...
When previously identifying causes of delay in cancer treatment, existing workflows often did not provide consistent timelines estimated for providers to diagnose and treat patients. To reduce time to treatment, researchers employed a pilot...
Telehealth technologies are emerging as transformative tools in health care. Implementing telehealth strategies allows providers to bridge the gap between access to support services, improving patient outcomes and overall experience. In a...
Telehealth technologies are emerging as transformative tools in health care. Implementing telehealth strategies allows providers to bridge the gap between access to support services, improving patient outcomes and overall experience. In a...
Ibrutinib, acalabrutinib, and zanubrutinib are Bruton tyrosine kinase inhibitors (BTKis) approved for treatment of chronic lymphocytic leukemia (CLL). In this study, researchers used data from package inserts, clinical trials, and real-world...
Ibrutinib, acalabrutinib, and zanubrutinib are Bruton tyrosine kinase inhibitors (BTKis) approved for treatment of chronic lymphocytic leukemia (CLL). In this study, researchers used data from package inserts, clinical trials, and real-world...
Systemic therapies for metastatic colorectal cancer (mCRC) have distinct safety and tolerability profiles. Adverse events (AEs) may occur and compromise the course of treatment, increase health care utilization and costs, and worsen patients’...
Systemic therapies for metastatic colorectal cancer (mCRC) have distinct safety and tolerability profiles. Adverse events (AEs) may occur and compromise the course of treatment, increase health care utilization and costs, and worsen patients’...
Drug waste poses a significant challenge in the field of health care, resulting in increased costs and environmental concerns. Using administrative claims data for Medicare patients from 15 practices in The US Oncology Network, researchers...
Drug waste poses a significant challenge in the field of health care, resulting in increased costs and environmental concerns. Using administrative claims data for Medicare patients from 15 practices in The US Oncology Network, researchers...
Conducting a thorough and systemic evaluation of practice readiness for value-based care (VBC) programs empowers practices to make informed decisions about VBC model participation. VBC programs like the Enhancing Oncology Model (EOM) offers...
Conducting a thorough and systemic evaluation of practice readiness for value-based care (VBC) programs empowers practices to make informed decisions about VBC model participation. VBC programs like the Enhancing Oncology Model (EOM) offers...
To fully understand and rectify impediments to optimal patient outcomes and experiences for patients with cancer, researchers reviewed health-related social needs (HRSN) to fully understand how to provide support to affected patients....
To fully understand and rectify impediments to optimal patient outcomes and experiences for patients with cancer, researchers reviewed health-related social needs (HRSN) to fully understand how to provide support to affected patients....
Manual electronic health records (EHR) can help bridge the gap between patients with cancer and survivorship resources. In this study, researchers conducted a pilot using a web-based clinical pathways decision-support platform to provide...
Manual electronic health records (EHR) can help bridge the gap between patients with cancer and survivorship resources. In this study, researchers conducted a pilot using a web-based clinical pathways decision-support platform to provide...
Delays in cancer treatment authorization often impede optimal patient care. In this retrospective assessment of payment rates, the Dana-Farber Cancer Institute explores payer approval decisions for on-pathway treatments.
Delays in cancer treatment authorization often impede optimal patient care. In this retrospective assessment of payment rates, the Dana-Farber Cancer Institute explores payer approval decisions for on-pathway treatments.
According to research published in the Journal of Clinical Oncology, clinical decision support (CDS) tools can foster an accelerated uptake of new therapies compared to non-users. In this study, researchers used a CDS tool called Flatiron...
According to research published in the Journal of Clinical Oncology, clinical decision support (CDS) tools can foster an accelerated uptake of new therapies compared to non-users. In this study, researchers used a CDS tool called Flatiron...
When previously identifying causes of delay in cancer treatment, existing workflows often did not provide consistent timelines estimated for providers to diagnose and treat patients. To reduce time to treatment, researchers employed a pilot...
When previously identifying causes of delay in cancer treatment, existing workflows often did not provide consistent timelines estimated for providers to diagnose and treat patients. To reduce time to treatment, researchers employed a pilot...
Telehealth technologies are emerging as transformative tools in health care. Implementing telehealth strategies allows providers to bridge the gap between access to support services, improving patient outcomes and overall experience. In a...
Telehealth technologies are emerging as transformative tools in health care. Implementing telehealth strategies allows providers to bridge the gap between access to support services, improving patient outcomes and overall experience. In a...
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the challenges and potential solutions for integrating cell and gene therapies—particularly CAR T—into clinical practice and insurance...
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the challenges and potential solutions for integrating cell and gene therapies—particularly CAR T—into clinical practice and insurance...
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the economic challenges of precision medicine in health care, including the differences between Medicare and commercial health plans and...
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the economic challenges of precision medicine in health care, including the differences between Medicare and commercial health plans and...